BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of pyridine derivatives as selective SHP2 inhibitors. 2020

Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin 300070, China; Department of Pharmacy, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261000, China.

SHP2 is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene, which affects the transduction of multiple signaling pathways, including RAS-ERK, PI3K-AKT and JAK-STAT. SHP2 also plays an important role in the programmed cell death pathway (PD-1/PD-L1). Studies have shown that SHP2 is associated with a variety of cancers, including breast, liver and gastric cancers. Therefore, the development of SHP2 inhibitors has attracted extensive attention. In this study, based on the known inhibitor 1 (SHP099), novel SHP2 inhibitors were designed by means of scaffold hopping, and 35 pyridine derivatives as SHP2 inhibitors were found. The in vitro enzyme activity assay was performed on these compounds, and multiple selective SHP2 inhibitors with activity potency similar to that of SHP099 were obtained. Among them, compound (2-(4-(aminomethyl)piperidin-1-yl)-5-(2,3-dichlorophenyl)pyridin-3-yl)methanol (11a) was the most potent and highly selective SHP2 inhibitor with an in vitro enzyme activity IC50 value of 1.36 μM. Fluorescence titration assay verified that 11a bound directly to SHP2 protein. Subsequently, cell assay of representative compounds showed that these compounds could effectively inhibit the proliferation of Ba/F3 cells. In addition, the pharmacokinetic characteristics of the designed compounds were analyzed by the in silico ADMET prediction. Molecular docking study provided more detailed information on the binding mode of compounds and SHP2 protein. In brief, this study reported for the first time that pyridine derivatives as novel SHP2 inhibitors had good inhibitory activity and selectivity, providing new clues for the development of small molecule SHP2 inhibitors.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D054592 Protein Tyrosine Phosphatase, Non-Receptor Type 11 A subtype of non-receptor protein tyrosine phosphatases that contain two SRC HOMOLOGY DOMAINS. Mutations in the gene for protein tyrosine phosphatase, non-receptor type 11 are associated with NOONAN SYNDROME. Phosphotyrosine Phosphatase Syp,Protein Tyrosine Phosphatase PTP3,Protein-Tyrosine-Phosphatase 2C,SHP-2 Protein-Tyrosine Phosphatase,SHP2 Phosphatase,SHPTP2,Shp-2 Tyrosine Phosphatase,Phosphatase, SHP2,Protein Tyrosine Phosphatase 2C,Protein Tyrosine Phosphatase, Non Receptor Type 11,Shp 2 Tyrosine Phosphatase,Tyrosine Phosphatase, Shp-2

Related Publications

Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of novel pyridine derivatives as gut-selective NaPi2b inhibitors.
June 2022, Bioorganic & medicinal chemistry letters,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis, and biological evaluation of novel triazoloquinazolinone derivatives as SHP2 protein inhibitors.
December 2021, Journal of enzyme inhibition and medicinal chemistry,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors.
August 2017, Bioorganic & medicinal chemistry letters,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of pyrazolo[3,4-b]pyridine derivatives as TRK inhibitors.
January 2023, RSC medicinal chemistry,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation.
August 2019, Journal of computer-aided molecular design,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.
November 2018, Bioorganic & medicinal chemistry,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of novel triazoloquinazolinone and imidazoquinazolinone derivatives as allosteric inhibitors of SHP2 phosphatase.
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
July 2016, Molecules (Basel, Switzerland),
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of hydantoin derivatives as Mcl-1 selective inhibitors.
April 2022, Bioorganic chemistry,
Wen-Shan Liu, and Bing Yang, and Rui-Rui Wang, and Wei-Ya Li, and Yang-Chun Ma, and Liang Zhou, and Shan Du, and Ying Ma, and Run-Ling Wang
Design, synthesis and biological evaluation of pyridine acyl sulfonamide derivatives as novel COX-2 inhibitors.
November 2011, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!